甲状腺乳头状癌microRNAs表达谱与临床相关性研究

目的 寻找甲状腺乳头状癌(PTC)中特异性表达的microRNAs,以提高PTC的早期诊断水平和判断PTC的侵袭性.方法 选取51例甲状腺手术组织标本,利用miRNA芯片技术寻找甲状腺良恶性结节之间有表达差异的microRNAs,并通过qRT-PCR验证差异性表达的microRNAs,分析其与PTC临床病理特征的相关性. 结果 (1)qRT-PCR结果显示miR-30a-3p(U=60,P=0.003),miR-146b-5p(U=40,P=0.001)及miR-199b-5p(U=69,P=0.007)在良恶性结节中存在差异性表达.(2)miR-199b-5p在包膜外浸润及颈侧区淋巴结转移的PTC患者中明显升高(P =0.010),侵袭性越强其表达越明显. 结论 miR-199b-5p,miR-30a-3p及miR-146b-5p能鉴别甲状腺结节的良恶性,miR-199b-5p与PTC的侵袭性正相关.     

微小RNA在糖尿病肾病患者血清中的表达及临床意义

目的 探讨糖尿病肾病发生、进展过程中血清微小RNA (microRNA,miRNA)表达谱及其临床意义.方法 应用miRNA基因芯片检测10例糖尿病肾病患者、10例糖尿病尿蛋白正常患者及10例健康对照者血清miRNA表达谱.实时荧光定量PCR法对66例糖尿病肾病(微量蛋白尿者36例,大量蛋白尿者30例)、40例糖尿病尿蛋白正常者及40例健康对照者进行血清miRNA表达谱验证,分析血清差异表达的miRNA与糖尿病肾病临床参数的关系.结果 实时荧光定量PCR法验证得到miR-150-5p、miR-155-5p、miR-30e-5p及miR-3196在糖尿病微量蛋白尿患者组(n=36)、糖尿病尿蛋白正常者组(n=40)及健康对照组(n=40)血清样本中表达差异有统计学意义(P＜0.05).miR-150-5p (P=0.005)和miR-155-5p (P=0.006)在糖尿病微量蛋白尿组(n=36)及糖尿病大量蛋白尿组(n=30)血清中表达差异有统计学意义.大量蛋白尿组血清miR-150-5p和miR-155-5p表达水平分别是微量蛋白尿组的2.3倍、1.5倍.同时发现,miR-150-5p和miR-155-5p与糖尿病肾病患者的估算肾小球滤过率和尿蛋白排泄率具有明显相关性.结论 miR-150-5p和miR-155-5p可能参与糖尿病肾病发生及发展的病理过程;血清miR-150-5p和miR-155-5p有望成为DN早期诊断及判断预后的潜在分子标志物.     

MiR-130b-3p在非小细胞肺癌患者血液中的表达及潜在意义

目的 探讨miR-130b-3p在NSCLC患者血液中的表达水平及潜在临床意义。方法 本研究使用癌症基因组图谱（TCGA）、基因表达谱数据库（GEO）以及序列片段归档数据库（SRA）下载了NSCLC相关的miRNAs表达谱,并提取miR-130b-3p在各个纳入的数据集中的表达量。计算标准化均数差（SMD）综合展示miR-130b-3p在NSCLC患者血液中的表达水平,进行诊断试验以探讨差异表达的miR-130b-3p对NSCLC患者和健康人的鉴别潜力。通过对miRwalk 2.0中12个数据库的预测结果进行交集,筛选出miR-130b-3p的下游靶基因,并采用富集分析探讨miR-130b-3p下游靶基因调控NSCLC的潜在信号通路。结果 共7项研究的300例NSCLC患者血液样本被纳入。miR-130b-3p在LUAD(SMD=-1.45,95%CI:-2.66～-0.23)以及LUSC(SMD=-0.46,95%CI:-0.84～-0.09)这两种NSCLC患者血液中的表达水平较对照组明显下调。诊断试验提示miR-130b-3p具有良好的区分NSCLC患者和健康人的潜力（AUC=0...     

微小RNA-27b-3p与基质金属蛋白酶13在人软骨细胞的对应关系

目的探讨微小RNA-27b-3p(miR-27b-3p)与基质金属蛋白酶-13(MMP-13)在人软骨细胞表达及其靶向对应关系。 方法运用蛋白质印迹法(WB)与实时定量PCR技术(qRT-PCR)明确miR-27b-3p与MMP13在正常和骨关节炎(OA)人软骨细胞的表达。利用不同浓度的白介素(IL)1β干预原代人软骨细胞24 h,或利用不同时间点的IL-1β(10 ng/ml)干预原代人软骨细胞。利用原位杂交、转染及双荧光素酶报告技术确定miR-27b-3p与MMP13的靶向对应关系;结合运用核转录因子-κB(NF-κB)和丝裂原活化蛋白激酶(MAPK)信号通路抑制剂评估其作用机制。两组资料比较采用独立样本t检验,多组资料比较采用单因素方差分析,LSD法多重比较检验。 结果WB、qRT-PCR和原位杂交检测结果显示,与正常软骨相比,OA软骨中miR-27b-3p表达降低(t＝5.07,P<0.01),MMP13表达升高(t＝－6.31,P<0.01)。IL-1β干扰后的结果显示miR-27b-3p表达降低(F＝129.54,P<0.05),MMP-13表达升高(F＝394.50,P<0.05)。通过TargetScan数据库和荧光素酶报告基因检测结果分析,野生型-MMP13组荧光素酶活性降低(F＝55.27,P<0.001),突变型-MMP-13荧光素酶活性变化没有统计学意义(P＝0.654)。利用特异性MAPK信号抑制剂和NF-kB抑制剂干预IL-1β诱导软骨细胞模型结果提示,与对照组相比,抑制剂组的MMP13表达水平降低(F＝28.43,P<0.001),miR-27b-3p表达水平增高(F＝35.04,P<0.001)。 结论miR-27b-3p在OA软骨细胞呈现低表达,并负向调控MMP13的表达,其作用机制可能是通过NF-κB和MAPK信号通路,这结果提示这miR-27b-3p可能作为OA诊断与治疗的潜在靶点。     

原发性局灶节段硬化性肾小球肾炎患者循环microRNA表达谱研究

目的:本研究通过芯片分析原发性局灶节段硬化性肾小球肾炎(p FSGS)患者血浆中microRNA(miRNA)表达谱变化,寻找与p FSGS相关的miRNA及其与临床指标的相关性。方法:采用Exiqon miRNA表达谱芯片技术,检测人成熟miRNA在p FSGS患者和健康对照中表达水平差异,应用分层聚类分析获得p FSGS差异表达的miRNA谱。并采用实时荧光定量PCR在扩大样本的FSGS患者中验证芯片结果。结果:(1)MiRNA芯片检测结果表明存在p FSGS特异性的miRNA表达谱,共筛选出95个差异表达的miRNA,均为低表达(P0.05)。(2)选取的4个表达差异较为显著的miRNA(miR-3678-3p,miR-4670-5p,miR-583,miR-30c-2-3p)进行定量PCR检测,其表达均低于正常对照组,其中miR-4670-5p、miR-583及miR-30c-2-3p三个差异较明显,比值均在0.5以下(P0.05),结果与芯片相符性较好。(3)纳入的12例患者,顶端型4例,非特异型8例,不同病理亚型,上述验证的4个miRNAs表达差异均无统计学意义(P0.05);Pearson相关性分析显示:miR-4670-5p表达量与BMI显著正相关(r=0.638,P=0.035);miR-583表达量与Scr正相关(r=0.672,P=0.047)、与GFR负相关(r=-0.723,P=0.028);miR-3678-3p和miR-30c-2-3p与患者GFR、BMI、Scr、Alb、24 h尿蛋白定量等指标无明显相关性(P0.05)。结论:多种miRNA在p FSGS患者血浆中异常表达,提示它们可能在FSGS的发生发展中起调控作用。     

微小RNA-146b-5p通过Robo1对胆囊癌细胞增殖和凋亡的影响

目的探讨微小RNA(miRNA, miR)-146b-5p通过Robo1对胆囊癌细胞增殖和凋亡的影响。方法选取郑州大学第一附属医院2017年1月到2021年12月手术切除的59例胆囊癌及其癌旁组织作为研究对象, 采用荧光定量聚合酶链反应(PCR)分析肿瘤组织和癌旁组织miR-146b-5p表达水平;采用免疫组织化学分析两种组织Robo1蛋白表达水平。采用转染试剂转染miRNA对照和miR-146b-5p抑制剂至人胆囊癌细胞系GBC-SD, 分别命名为miRNA对照组和miR-146b-5p KD组, 采用噻唑蓝(MTT)和克隆形成实验分析两组细胞活力和增殖能力;采用划痕实验、Transwell和蛋白质印迹法(Western blot)分析两组细胞迁移、侵袭和上皮-间充质转化能力;采用生物信息学和荧光素酶报告基因分析miR-146b-5p的靶基因;采用Western blot分析靶基因表达水平。计量数据比较采用t检验。结果胆囊癌组织miR-146b-5p表达水平(1.01±0.16)明显低于癌旁组织(1.94±0.30), 差异有统计学意义(t=20.860, P<0.05)。mi...     

微小RNA-29b-3p对大鼠膝骨关节炎模型的保护作用及其机制

目的探讨微小RNA(miR)-29b-3p对大鼠膝骨关节炎模型的保护作用及其机制。方法 30只SD大鼠随机分为对照组、模型组和miR-29b-3p KD组, miR-29b-3p KD组大鼠经膝关节腔注射过表达miR-29b-3p沉默腺相关病毒, 对照组和模型组经膝关节腔给予对照腺相关病毒。3组大鼠表达30 d后, 模型组和miR-29b-3p KD组大鼠采用木瓜蛋白酶局部注射复制膝骨关节炎动物模型。建模4周后, 采用荧光定量聚合酶链反应(PCR)分析膝关节miR-29b-3p表达水平;Mankin组织学评分和Pelletier评分分析关节炎病变程度;分析3组大鼠膝关节最大活动度;采用酶联免疫吸附实验分析白细胞介素(IL)-1β、肿瘤坏死因子-α(TNF-α)和转化生长因子-β1(TGF-β1)水平;采用免疫组织化学分析基质金属蛋白酶(MMP)-13和Ⅱ型胶原的表达水平。组间比较采用单因素方差分析。结果 miR-29b-3p KD组大鼠膝关节组织miR-29b-3p表达水平(0.76±0.11)明显低于模型组(2.09±0.15), 差异有统计学意义(t=22.240, P<0....     

长链非编码核糖核酸LINC00261通过miR-148b-3p/PTEN途径对高糖环境中HK-2细胞的保护作用

目的探讨长链非编码RNA(lncRNA)LINC00261在糖尿病肾病中的表达,及其可能通过微小核糖核酸miR-148b-3p/PTEN途径对高糖环境中HK-2细胞的保护作用。 方法选择2016年3月至2018年5月本院的19例糖尿病肾病患者和23例健康对照者,采集血样,通过实时定量PCR(qRT-PCR)测定LINC00261和miR-148b-3p的表达。在细胞实验中,将HK-2肾小管上皮细胞分为7组：正常葡萄糖组(5.5 mmol/L培养,NG组)、高葡萄糖糖组(30.0 mmol/L培养,HG组)、其余5组也均为高葡萄糖培养：空质粒转染pcDNA(HG+pcDNA组)、转染LINC00261(HG+pcDNA-LINC00261组)、转染阴性对照anti-miR-NC(HG+anti-miR-NC组)、转染抑制剂anti-miR-148b-3p(HG+anti-miR-148b-3p组)、LncRNA和miRNA同时转染(HG+pcDNA-LINC0026+miR-148b-3p组)。应用Western印迹、细胞计数试剂盒8和流式细胞术分别检测PTEN蛋白表达、细胞增殖与凋亡。测超氧化物歧化酶(SOD)试剂盒和丙二醛(MDA)试剂盒分别检测SOD活性和MDA含量。双荧光素酶报告实验用于LINC00261、miR-148b-3p、PTEN的相互关系鉴定。 结果与健康对照者比较,糖尿病肾病患者的LINC00261表达明显降低,而miR-148b-3p表达则明显增高(P<0.05)。过表达LINC00261或抑制miR-148b-3p后,高糖环境中HK-2细胞的miR-148b-3p表达、细胞凋亡及MDA含量均下降,而PTEN蛋白表达、细胞增殖及SOD活性均增高(P<0.05)。 结论LINC00261可能通过调控miR-148b-3p/PTEN途径,促进高糖环境中HK-2肾小管上皮细胞增殖、降低氧化应激、减少细胞凋亡。     

血清miR-135-5p及miR-337-5p在糖尿病肾病中的表达及其临床意义

目的探讨糖尿病肾病(DN)患者的血清miR-135-5p及miR-337-5p表达及其临床意义。方法选取2018年1月至2020年12月本院收治的105例2型DN患者和60例体检正常者(对照组)。根据尿白蛋白排泄率(UAER)将105例2型DN患者分为早期DN组57例(UAER为20～200 μg/min)和临床期DN组48例(UAER>200 μg/min)。比较各组血清miR-135-5p及miR-337-5p表达水平, 应用多因素logistic回归分析影响DN发生的危险因素。绘制受试者工作特征(ROC)曲线分析血清miR-135-5p及miR-337-5p表达水平在诊断DN中的价值。结果 DN组的血清miR-135-5p及miR-337-5p表达水平均明显高于对照组(均P<0.001)。临床期DN组的血清miR-135-5p及miR-337-5p表达水平均明显高于早期DN组(均P<0.001)。多因素logistic回归分析显示, 血清miR-135-5p及miR-337-5p表达水平升高是影响DN发生的独立危险因素(均P<0.001)。ROC曲线分析显...     

强直性脊柱炎患者外周血单个核细胞微小RNA的差异表达

目的 探讨强直性脊柱炎患者和健康对照组外周血单个核细胞已知微小RNA(miRNA)差异表达.方法 分别构建10例强直性脊柱炎患者和9例健康对照组外周血单个核细胞小RNA文库,并运用新一代高通量Solexa测序技术,进行外周血单个核细胞已知miRNA的检测;运用实时荧光定量聚合酶链反应(FQ-PCR)进一步验证部分差异miRNA表达.结果 在强直性脊柱炎患者与对照组中小RNA文库中,共获得小RNA总量分别是7511 859和10 178 958,比对上基因组部分小RNA分别是6052911 (80.58％)和8 476 243(83.27％);已知miRNA分别是267和231个,通过miRNA差异性分析,129个上调miRNA和28个下调miRNA,其表达水平差异有统计学意义(P＜0.05);FQ-PCR进一步验证了let-7b-3p、miR-146a-5p、miR-155-5p、let-7g-5p和miR-323a-5p差异表达水平与Solexa测序结果相似趋势.结论 强直性脊柱炎患者外周血单个核细胞miRNA的差异表达,可能与强直性脊柱炎发病密切相关.     

Serum miRNAs as potential biomarkers for the bronchiolitis obliterans syndrome after lung transplantation

Lung transplantation (LTx) is the last treatment for patients suffering from end-stage lung diseases. Survival post-LTx is hampered by the development of the bronchiolitis obliterans syndrome (BOS) and diagnosis is often late. Given the urgent clinical need to recognize BOS patients at an early stage, we analyzed circulating miRNAs to identify possible stratification markers for BOS development post-transplantation. Therefore, pro-fibrotic (miR-21, miR-155), anti-fibrotic (miR-29a) and fibrosis-unrelated (miR-103, miR-191) miRNAs were analyzed in serum of end-stage lung disease patients and during LTx follow-up.Significant elevated levels of serum miRNAs were observed for all investigated miRNAs in both chronic obstructive pulmonary disease and interstitial lung disease patients compared to healthy controls. The same miRNAs were also significantly increased in the serum of BOS + vs. BOS − patients. Most importantly, miR-21, miR-29a, miR-103, and miR-191 levels were significantly higher in BOS + patients prior to clinical BOS diagnosis.We demonstrated that a selected group of miRNAs investigated is elevated in end-stage lung disease and BOS + patients, prior to clinical BOS diagnosis. Even if further research is expedient on the prognostic value of circulating miRNAs in BOS and lung conditions in general, these results strongly suggest that circulating miRNAs could be used as potential biomarkers for BOS development.     

Circulating TGF-β1–Regulated miRNAs and the Risk of Rapid Progression to ESRD in Type 1 Diabetes

We investigated whether circulating TGF-β1–regulated miRNAs detectable in plasma are associated with the risk of rapid progression to end-stage renal disease (ESRD) in a cohort of proteinuric patients with type 1 diabetes (T1D) and normal eGFR. Plasma specimens obtained at entry to the study were examined in two prospective subgroups that were followed for 7–20 years (rapid progressors and nonprogressors), as well as a reference panel of normoalbuminuric T1D patients. Of the five miRNAs examined in this study, let-7c-5p and miR-29a-3p were significantly associated with protection against rapid progression and let-7b-5p and miR-21-5p were significantly associated with the increased risk of ESRD. In logistic analysis, controlling for HbA_1c and other covariates, let-7c-5p and miR-29a-3p were associated with more than a 50% reduction in the risk of rapid progression (P ≤ 0.001), while let-7b-5p and miR-21-5p were associated with a >2.5-fold increase in the risk of ESRD (P ≤ 0.005). This study is the first prospective study to demonstrate that circulating TGF-β1–regulated miRNAs are deregulated early in T1D patients who are at risk for rapid progression to ESRD.     

A Signature of Circulating miRNAs Associated With Fibrous Dysplasia of Bone: the mirDys Study

Fibrous dysplasia (FD) is a rare bone disease caused by activating mutations of GNAS encoding the Gsα protein, enhancing cyclic adenosine monophosphate (cAMP) production by overstimulation of adenylyl cyclase and impairing osteoblastic differentiation. The clinical presentation ranges from asymptomatic to polyostotic forms with severe disability, explained by the mosaic distribution of the GNAS mutation. Physicians have to deal with the gap of knowledge in FD pathogenesis, the absence of prognostic markers and the lack of specific treatment. The identification of specific biomarkers for FD is an important step to improve the clinical and therapeutic approaches. An epigenetic regulation driven by microRNAs (miRNAs), known as promising biomarkers in bone disease, could be involved in FD. We have sought circulating miRNAs that are differentially expressed in FD patients compared to controls and would reflect dysregulations of osteogenesis-related genes and bone disorder. The global miRNA profiling was performed using Next Generation Sequencing in patient serum collected from a discovery cohort of 20 patients (10 polyostotic and 10 monostotic) and 10 controls. From these, we selected 19 miRNAs for a miRNA validation phase from serum of 82 patients and 82 controls, using real-time qPCR. Discovery screening identified 111 miRNAs differentially expressed in patient serum, after adjusting for the false discovery rate (FDR). Among the 82 patients, 55% were polyostotic, and 73% were women with a mean age of 42 years. Six miRNAs (miR-25-3p, miR-93-5p, miR-182-5p, miR-324-5p, miR-363-3p, and miR-451a) were significantly overexpressed in serum, with FDR <0.05. The expression level of these six miRNAs was not associated with the FD severity. In conclusion, we identified a signature of circulating miRNAs associated with FD. These miRNAs are potential negative regulators of gene expression in bone cell progenitors, suggesting their activity in FD by interfering with osteoblastic and osteoclastic differentiation to impair bone mineralization and remodeling processes. © 2020 American Society for Bone and Mineral Research.     

Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis

MicroRNAs regulate bone homeostasis, and circulating microRNAs have been proposed as novel bone biomarkers. The effect of anti-osteoporotic treatment on circulating microRNAs has not been described in detail. Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized (OVX) and sham-operated (SHAM) rats over 12 weeks of antiresorptive or osteoanabolic treatment. Forty-two Sprague Dawley rats underwent SHAM surgery (n = 10) or ovariectomy (n = 32). After 8 weeks, OVX rats were randomized to antiresorptive treatment with zoledronate (n = 11), osteoanabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10). Serum samples were collected at weeks 8, 12, 16, and 20 after surgery. A total of 91 microRNAs were analyzed by RT-qPCR in serum samples collected at week 20. Based on the results, 29 microRNAs were selected for longitudinal analysis at all four study time points. Changes in bone mineral density and microstructure were followed up by in vivo micro-CT and ex vivo nano-CT. Ovariectomy resulted in the loss of trabecular bone, which was reversed by osteoanabolic and antiresorptive treatment. Differential expression analysis identified 11 circulating miRNAs that were significantly regulated after treatment. For example, miR-107 and miR-31-5p increased in vehicle-treated OVX animals, whereas they decreased during teriparatide treatment. Additional miRNAs were identified that showed significant correlations to bone microstructure or bone miRNA expression, including miR-203a-3p, which exhibited a significant negative correlation to vertebral and tibial trabecular bone volume fraction (%). Longitudinal analysis confirmed eight microRNAs with significant changes in serum over time that were prevented by teriparatide and zoledronate treatment (miR-34a-5p, miR-31-5p, miR-30d-3p, miR-378a-5p) or teriparatide treatment only (miR-375-3p, miR-183-5p, miR-203a-3p, miR-203b-3p). Gene target network analysis identified WNT and Notch signaling as the main signaling pathways controlled by these miRNAs. Thus, ovariectomy results in time-dependent deregulation of circulating miRNAs compared with SHAM animals. Anti-osteoporotic treatments can rescue this effect, showing that bone-related miRNAs might act as novel biomarkers for treatment monitoring. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).     

miR-18a-3p在肝癌中的表达及其调控ADCY1表达对肝癌细胞侵袭及增殖的影响

背景与目的 研究表明多种microRNA（miRNA）可能在肝癌的发生发展中发挥重要作用,其作用机制仍值得进一步研究和探讨。因此,本研究从已报道的肝癌差异表达miRNA中进一步筛选关键miRNA,并验证和探讨其作用机制。方法 从已发表的研究中筛选出肝癌组织及肝癌患者血清/血浆中与正常肝组织及正常血清/血浆中共同的差异表达miRNA;用qRT-PCR在正常肝细胞与肝癌细胞中对筛选出的目标miRNA表达情况进行验证;用过表达和抑制的方法观察目标miRNA对肝癌细胞侵袭能力（Transwell实验）与增殖能力（MTT实验）的影响,以及在30例临床标本中检测目标miRNA的表达并通过KM plotter网站分析其对肝癌患者生存的影响;通过miRDB和GEPIA数据库预测和分析目标miRNA的靶基因,并用逆转实验和双荧光素酶报告实验进一步验证。结果 在肝癌组织（vs.正常肝组织）及肝癌患者血清/血浆（vs.正常人血清/血浆）中共同高表达的miRNA有4个（miR-18a-3p、miR-221-3p、miR-222-3p、miR-224-3p）,共同低表达的miRNA有2个（miR-26a-3p、miR-125b-3p）。qRT-PCR实验证实,与正常肝细胞比较,miR-18a在肝癌细胞中高表达,miR-26a在肝癌细胞中低表达（均P<0.05）。过表达/抑制miR-18a-3p表达能促进/降低肝癌细胞的侵袭及生长能力（均P<0.05）,而过表达/抑制miR-26a-3p对肝癌细胞的侵袭及生长能力影响无不法确定。分析结果显示,ADCY1是miR-18a-3p的靶基因,过表达ADCY1能部分逆转miR-18a-3p对肝癌细胞的上述作用,同时,表达上调的miR-18a-3p能通过结合到ADCY1 mRNA 3''UTR抑制ADCY1的表达。结论 miR-18a-3p可能在肝癌的发生发展中起了关键作用,其在肝癌中表达上调,并能通过抑制下游靶基因ADCY1的表达增强进肝癌细胞的侵袭和增殖能力。     

Differentially expressed microRNA in testicular tissues of hyperuricaemia rats

This study is to identify the differentially expressed miRNAs in testicular tissues of rats with hyperuricaemia-induced male infertility. We found that the hyperuricaemia model group had significantly increased serum uric acid, while significantly decreased sperm concentration and motile sperm percentage than normal group (p < .05). A total of 39 differentially expressed miRNAs were identified in the testicular tissues of hyperuricaemia rats compared with the control rats, ten of which were validated by real-time PCR. The target mRNAs of 7 differentially expressed miRNAs (miR-10b-5p, miR-26a-5p, miR-136-5p, miR-151-3p, miR-183-5p, miR-362-3p and miR-509-5p) from 3’-untranslated region binding perspective were enriched in signalling pathways of Wnt, Jak-STAT, mTOR and MAPK. The target mRNAs of 6 differentially expressed miRNAs (miR-136-5p, miR-144-3p, miR-99a-5p, miR-509-5p, miR-451-5p and miR-362-3p) from coding sequence binding perspective were enriched in signalling pathways of Calcium, Notch and MAPK. The functions of miRNAs in testicular tissues of rats with hyperuricaemia were revealed by the differentially expressed miRNAs (miR-183-5p, miR-99a-5p, miR-10b-5p, miR-151-3p, miR-26a-5p, miR-451-5p, miR-362-3p, miR-136-5p, miR-144-3p and miR-509-5p)–mRNAs interaction network. The differentially expressed miRNAs in the testicular tissues of hyperuricaemia rats might shed light on the mechanism of hyperuricaemia-induced male infertility.     

miR-34b-5p promotes renal cell inflammation and apoptosis by inhibiting aquaporin-2 in sepsis-induced acute kidney injury

ObjectiveThis study was designed to uncover the mechanism of miR-34b-5p-mediated aquaporin-2 (AQP2) in sepsis-induced injury using human renal tubular epithelial cells (HK-2).MethodsSerum levels of miR-34b-5p, TNF-α, IL-1β, IL-6, serum creatinine (SCr), and blood urea nitrogen (BUN) in septic patients with acute kidney injury (AKI) and healthy controls were detected. Lipopolysaccharide (LPS) was used to induce sepsis in HK-2 cells. LPS-induced HK-2 cells were transfected with miR-34b-5p inhibitor, miR-34b-5p mimic, pcDNA3.1-AQP2, si-AQP2, miR-34b-5p inhibitor + si-NC, or miR-34b-5p inhibitor + si-AQP2. The expressions of miR-34b-5p, AQP2, Bax, Bcl-2, cleaved caspase-3, TNF-α, IL-1β, and IL-6 in HK-2 cells were detected. TUNEL staining revealed the apoptosis of HK-2 cells. Dual-luciferase reporter assay verified the binding between miR-34b-5p and AQP2.ResultsThe expression of miR-34b-5p and the inflammatory responses were augmented in septic AKI patients. miR-34b-5p was up-regulated and AQP2 was down-regulated in LPS-induced HK-2 cells. miR-34b-5p inhibition or AQP2 overexpression ameliorated apoptosis and inflammation in LPS-induced HK-2 cells. In contrast, overexpressing miR-34b-5p deteriorated LPS-induced injury in HK-2 cells. AQP2 was a downstream target of miR-34b-5p. AQP2 silencing abolished the suppressive effects of miR-34b-5p inhibition on LPS-induced apoptosis and inflammatory response in HK-2 cells.ConclusionmiR-34b-5p inhibits AQP2 to promote LPS-induced injury in HK-2 cells.